Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Golabek, 2016, Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer, Cent European J Urol, 69, 131, 10.5173/ceju.2016.812
Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7
Beer, 2016, Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study, Eur Urol, 71, 151, 10.1016/j.eururo.2016.07.032
Karantanos, 2015, Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level, Eur Urol, 67, 470, 10.1016/j.eururo.2014.09.049
Imamura, 2016, Androgen receptor targeted therapies in castration-resistant prostate cancer: bench to clinic, Int J Urol, 23, 654, 10.1111/iju.13137
Sadar, 1999, Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways, J Biol Chem, 274, 7777, 10.1074/jbc.274.12.7777
Ueda, 2002, Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways, J Biol Chem, 277, 7076, 10.1074/jbc.M108255200
Lin, 2003, Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers, J Biol Chem, 278, 50902, 10.1074/jbc.M300676200
Gregory, 2004, Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer, J Biol Chem, 279, 7119, 10.1074/jbc.M307649200
Wen, 2000, HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway, Cancer Res, 60, 6841
Nazareth, 1996, Activation of the human androgen receptor through a protein kinase A signaling pathway, J Biol Chem, 271, 19900, 10.1074/jbc.271.33.19900
Jenster, 1992, Functional domains of the human androgen receptor, J Steroid Biochem Mol Biol, 41, 671, 10.1016/0960-0760(92)90402-5
Chamberlain, 1996, Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain, J Biol Chem, 271, 26772, 10.1074/jbc.271.43.26772
Smith, 2008, Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions, Mol Endocrinol, 22, 2229, 10.1210/me.2008-0089
Ozanne, 2000, Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin, Mol Endocrinol, 14, 1618, 10.1210/mend.14.10.0541
Loy, 2003, Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions, Proc Natl Acad Sci U S A, 100, 4562, 10.1073/pnas.0736237100
Migliaccio, 2000, Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation, EMBO J, 19, 5406, 10.1093/emboj/19.20.5406
Zarif, 2015, Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase, Oncotarget, 6, 6862, 10.18632/oncotarget.3119
Migliaccio, 2007, Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth, Oncogene, 26, 6619, 10.1038/sj.onc.1210487
Unni, 2004, Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence, Cancer Res, 64, 7156, 10.1158/0008-5472.CAN-04-1121
Berns, 1986, Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP, Prostate, 9, 247, 10.1002/pros.2990090305
Olea, 1990, The proliferative effect of “anti-androgens” on the androgen-sensitive human prostate tumor cell line LNCaP, Endocrinology, 126, 1457, 10.1210/endo-126-3-1457
de Launoit, 1991, Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells, Cancer Res, 51, 5165
Castoria, 2003, Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action, J Cell Biol, 161, 547, 10.1083/jcb.200211099
Castoria, 2011, Androgen-induced cell migration: role of androgen receptor/filamin A association, PLoS One, 6, e17218, 10.1371/journal.pone.0017218
Castoria, 2014, Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells, Cell Death Dis, 5, e1548, 10.1038/cddis.2014.497
Bedolla, 2009, Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases, Clin Cancer Res, 15, 788, 10.1158/1078-0432.CCR-08-1402
Ghosh, 2005, Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation, Endocr Relat Cancer, 12, 119, 10.1677/erc.1.00835
Peterziel, 1999, Rapid signalling by androgen receptor in prostate cancer cells, Oncogene, 18, 6322, 10.1038/sj.onc.1203032
Yang, 1998, The Elk-1 ETS-domain transcription factor contains a mitogen-activated protein kinase targeting motif, Mol Cell Biol, 18, 710, 10.1128/MCB.18.2.710
Marais, 1993, The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain, Cell, 73, 381, 10.1016/0092-8674(93)90237-K
Bonni, 1999, Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms, Science, 286, 1358, 10.1126/science.286.5443.1358
Gelman, 2014, Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases, Int J Biol Sci, 10, 620, 10.7150/ijbs.8264
Posadas, 2009, FYN is overexpressed in human prostate cancer, BJU Int, 103, 171, 10.1111/j.1464-410X.2008.08009.x
Zardan, 2014, Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer, Oncogenesis, 3, e115, 10.1038/oncsis.2014.30
Asim, 2008, Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells, Oncogene, 27, 3596, 10.1038/sj.onc.1211016
Varkaris, 2014, Src signaling pathways in prostate cancer, Cancer Metastasis Rev, 33, 595, 10.1007/s10555-013-9481-1
Nam, 2005, Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells, Cancer Res, 65, 9185, 10.1158/0008-5472.CAN-05-1731
Lombardo, 2004, Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J Med Chem, 47, 6658, 10.1021/jm049486a
Recchia, 2003, Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro, Eur J Cancer, 39, 1927, 10.1016/S0959-8049(03)00394-0
Baron, 2004, Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells, J Biol Chem, 279, 14579, 10.1074/jbc.M306143200
Yang, 2005, Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells, J Biol Chem, 280, 33558, 10.1074/jbc.M504461200
Liu, 2008, A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells, Cancer Res, 68, 10290, 10.1158/0008-5472.CAN-08-2038
Taylor, 2010, Integrative genomic profiling of human prostate cancer, Cancer Cell, 18, 11, 10.1016/j.ccr.2010.05.026
Gioeli, 2012, Post-translational modification of the androgen receptor, Mol Cell Endocrinol, 352, 70, 10.1016/j.mce.2011.07.004
Mahajan, 2007, Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation, Proc Natl Acad Sci U S A, 104, 8438, 10.1073/pnas.0700420104
Guo, 2006, Regulation of androgen receptor activity by tyrosine phosphorylation, Cancer Cell, 10, 309, 10.1016/j.ccr.2006.08.021
DaSilva, 2009, The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor, Cancer Res, 69, 7402, 10.1158/0008-5472.CAN-08-4687
Blaszczyk, 2004, Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells, Clin Cancer Res, 10, 1860, 10.1158/1078-0432.CCR-0974-3
Lee, 2004, Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK, Oncogene, 23, 2197, 10.1038/sj.onc.1207344
Roberts, 2007, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer, Oncogene, 26, 3291, 10.1038/sj.onc.1210422
Ponguta, 2008, Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer, J Biol Chem, 283, 20989, 10.1074/jbc.M802392200
Turkson, 1998, Stat3 activation by Src induces specific gene regulation and is required for cell transformation, Mol Cell Biol, 18, 2545, 10.1128/MCB.18.5.2545
Garcia, 2001, Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells, Oncogene, 20, 2499, 10.1038/sj.onc.1204349
Ueda, 2002, Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells, J Biol Chem, 277, 38087, 10.1074/jbc.M203313200
Lin, 2001, Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor, Proc Natl Acad Sci U S A, 98, 7200, 10.1073/pnas.121173298
Gomella, 2009, Effective testosterone suppression for prostate cancer: is there a best castration therapy?, Rev Urol, 11, 52
Heyns, 2003, Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer, BJU Int, 92, 226, 10.1046/j.1464-410X.2003.04308.x
Mohler, 2004, The androgen axis in recurrent prostate cancer, Clin Cancer Res, 10, 440, 10.1158/1078-0432.CCR-1146-03
Efstathiou, 2015, Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer, Eur Urol, 67, 53, 10.1016/j.eururo.2014.05.005
Clegg, 2012, ARN-509: a novel antiandrogen for prostate cancer treatment, Cancer Res, 72, 1494, 10.1158/0008-5472.CAN-11-3948
Fizazi, 2014, Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial, Lancet Oncol, 15, 975, 10.1016/S1470-2045(14)70240-2
Carver, 2011, Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer, Cancer Cell, 19, 575, 10.1016/j.ccr.2011.04.008
Sun, 2010, Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant, J Clin Invest, 120, 2715, 10.1172/JCI41824
Guo, 2009, A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth, Cancer Res, 69, 2305, 10.1158/0008-5472.CAN-08-3795
Pandini, 2005, Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells, Cancer Res, 65, 1849, 10.1158/0008-5472.CAN-04-1837
Yang, 2011, Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells, J Biol Chem, 286, 36152, 10.1074/jbc.M111.265124
Jagla, 2007, A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions, Endocrinology, 148, 4334, 10.1210/en.2007-0446
Andersen, 2010, Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor, Cancer Cell, 17, 535, 10.1016/j.ccr.2010.04.027
Banuelos, 2016, Sintokamide A is a novel antagonist of androgen receptor that uniquely binds activation function-1 in its amino-terminal domain, J Biol Chem, 291, 22231, 10.1074/jbc.M116.734475
Yang, 2016, Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer, Clin Cancer Res, 22, 4466, 10.1158/1078-0432.CCR-15-2901
De Mol, 2016, EPI-001, A compound active against castration-resistant prostate cancer, targets transactivation unit 5 of the androgen receptor, ACS Chem Biol, 11, 2499, 10.1021/acschembio.6b00182
Yu, 2014, Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor, Clin Cancer Res, 20, 4075, 10.1158/1078-0432.CCR-14-0292
Purushottamachar, 2013, Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer, J Med Chem, 56, 4880, 10.1021/jm400048v
Liu, 2014, Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer, Clin Cancer Res, 20, 3198, 10.1158/1078-0432.CCR-13-3296
Yu, 2015, Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687, J Nucl Med, 56, 354, 10.2967/jnumed.114.146936
Araujo, 2013, Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial, Lancet Oncol, 14, 1307, 10.1016/S1470-2045(13)70479-0
Posadas, 2016, Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: a University of Chicago phase 2 consortium and DOD/PCF prostate cancer clinical trials consortium study, Prostate, 76, 286, 10.1002/pros.23119
Antonarakis, 2013, A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer, Cancer Chemother Pharmacol, 71, 883, 10.1007/s00280-013-2079-z
Bitting, 2013, Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer, Endocr Relat Cancer, 20, R83, 10.1530/ERC-12-0394
Statz, 2016, mTOR inhibitors in castration-resistant prostate cancer: a systematic review, Target Oncol, 10.1007/s11523-016-0453-6
Toren, 2015, Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models, Eur Urol, 67, 986, 10.1016/j.eururo.2014.08.006
Ramamurthy, 2015, Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines, Oncotarget, 6, 3195, 10.18632/oncotarget.3084
Sarker, 2009, Targeting the PI3K/AKT pathway for the treatment of prostate cancer, Clin Cancer Res, 15, 4799, 10.1158/1078-0432.CCR-08-0125